v3.26.3
Significant Accounting Policies (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Dec. 31, 2022
Significant Accounting Policies [Line Items]              
Issuance date fair value       $ 36,626   $ 6,242  
Deferred income $ 857   $ 857 857   $ 1,269  
Gain from sale of IP       5,821      
Non refundable consideration             $ 2,000
Other income 487 $ 408   9,347 $ 665    
Excess cost       6,500      
Investor relations expenses 68     176      
Variable interest entity [Member]              
Significant Accounting Policies [Line Items]              
Interest $ 24,897   $ 24,897 $ 24,897      
Alpha Tau [Member]              
Significant Accounting Policies [Line Items]              
Purchase warrants 3,237,000   3,237,000 3,237,000      
Issuance date fair value       $ 2,727      
Semi-annual payments       500      
Total semi-annual payments       3,000      
Deferred income $ 63   $ 63 63      
Other income 227     682      
Clinical Trial Management Agreement with Oratech Ltd. [Member]              
Significant Accounting Policies [Line Items]              
Recognized income 74     167      
Deferred income 808   808 808      
Oratech Ltd. [Member]              
Significant Accounting Policies [Line Items]              
Excess cost       6,500      
Payments for services       6,500      
Medicox License Agreement [Member]              
Significant Accounting Policies [Line Items]              
Other income       2,000      
Services Agreement [Member]              
Significant Accounting Policies [Line Items]              
Other income       250      
Services Agreement [Member] | Alpha Tau [Member]              
Significant Accounting Policies [Line Items]              
Other income       750      
Other income, net 409     1,256      
Services Agreement [Member] | Alpha Tau [Member] | Alpha Tau Warrant [Member]              
Significant Accounting Policies [Line Items]              
Other income 477     1,432      
Clinical Trial Management Agreement [Member]              
Significant Accounting Policies [Line Items]              
Recognized income 78     270      
Deferred income 975   975 $ 975      
Clinical Trial Management Agreement [Member] | Oratech Ltd. [Member]              
Significant Accounting Policies [Line Items]              
Services and expenses $ 492   $ 1,114